Viridian Therapeutics (VRDN) Company presentation summary

Strategic vision and market opportunity

• Aims to lead in autoimmune diseases, starting with thyroid eye disease (TED), addressing unmet needs and expanding the treated patient population.

• TED market estimated at $2B annually, with low penetration and significant growth potential for new entrants.

• Focused on differentiated products and pipeline expansion in TED and broader autoimmune indications.

Product portfolio and pipeline

• Lumvoa (veligrotug-vvze) is FDA approved for both active and chronic TED, with strong clinical data and rapid symptom relief.

• Elegrobart, a subcutaneous anti-IGF-1R, showed positive pivotal trial results in both active and chronic TED; BLA submission anticipated Q1 2027.

• Pipeline includes TSHR inhibitor and FcRn-targeting agents (VRDN-006, VRDN-008) for TED, Graves’ disease, and other autoimmune conditions.

Clinical trial highlights

• Lumvoa pivotal trials (THRIVE, THRIVE-2) met all primary and secondary endpoints, demonstrating rapid and durable efficacy with a favorable safety profile.

• Elegrobart pivotal trials (REVEAL-1, REVEAL-2) achieved high statistical significance on primary endpoints, with rapid onset, robust proptosis and diplopia benefits, and generally mild adverse events.

• Both Q4W and Q8W dosing regimens for elegrobart were effective, with potential for at-home self-administration via autoinjector.